Hyung Soon Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hyung Soon Park has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Byoung Yong Shim
St. Vincent’s Hospital 6 Department of Medical Oncology The College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
2 shared publications Sung Shim Cho
Division of Medical Oncology, Department of Internal Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
2 shared publicationsDer Sheng Sun
Department of Internal Medicine College of Medicine The Catholic University of Korea Seoul Korea
1 shared publication- Der Sheng Sun
Division of Medical Oncology, Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
1 shared publication - Guk Jin Lee
Division of Medical Oncology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
1 shared publication - Hei-Cheul Jeung
Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine
1 shared publication
Latest Publications
- Open Access
- 15 March 2024
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 58 (2) , 49-58
Exploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non–small cell lung cancer
Treatment challenges persist in advanced lung cancer despite the development of therapies beyond the traditional platinum-based chemotherapy. The early 2000s marked a shift to tyrosine kinase inhibitors targeting epidermal growth factor receptor, ushering in personalized genetic-based treatment. A further significant advance was the development of immune checkpoint inhibitors (ICIs), especially for non–small cell lung cancer. These target programmed death-ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4, which enhanced the immune response against tumor cells. However, not all patients respond, and immune-related toxicities arise. This review emphasizes identifying biomarkers for ICI response prediction. While PD-L1 is a widely used, validated biomarker, its predictive accuracy is imperfect. Investigating tumor-infiltrating lymphocytes, tertiary lymphoid structure, and emerging biomarkers such as high endothelial venule, Human leukocyte antigen class I, T-cell immunoreceptors with Ig and ITIM domains, and lymphocyte activation gene-3 counts is promising. Understanding and exploring additional predictive biomarkers for ICI response are crucial for enhancing patient stratification and overall care in lung cancer treatment.
- 15 March 2024
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 58 (2) , 49-58
Open AccessExploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non–small cell lung cancer
Treatment challenges persist in advanced lung cancer despite the development of therapies beyond the traditional platinum-based chemotherapy. The early 2000s marked a shift to tyrosine kinase inhibitors targeting epidermal growth factor receptor, ushering in personalized genetic-based treatment. A further significant advance was the development of immune checkpoint inhibitors (ICIs), especially for non–small cell lung cancer. These target programmed death-ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4, which enhanced the immune response against tumor cells. However, not all patients respond, and immune-related toxicities arise. This review emphasizes identifying biomarkers for ICI response prediction. While PD-L1 is a widely used, validated biomarker, its predictive accuracy is imperfect. Investigating tumor-infiltrating lymphocytes, tertiary lymphoid structure, and emerging biomarkers such as high endothelial venule, Human leukocyte antigen class I, T-cell immunoreceptors with Ig and ITIM domains, and lymphocyte activation gene-3 counts is promising. Understanding and exploring additional predictive biomarkers for ICI response are crucial for enhancing patient stratification and overall care in lung cancer treatment.
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Gastric Cancer
- Vol. 23 (2) , 315-327
A Randomized Phase III Study of Patients With Advanced Gastric Adenocarcinoma Without Progression After Six Cycles of XELOX (Capecitabine Plus Oxaliplatin) Followed by Capecitabine Maintenance or Clinical Observation
Lee GJ, et al. J Gastric Cancer. 2023 Mar;23:e16. https://doi.org/10.5230/jgc.2023.23.e16
- 1 January 2023
- Published by XMLink in Journal of Gastric Cancer
- Vol. 23 (2) , 315-327
Open AccessA Randomized Phase III Study of Patients With Advanced Gastric Adenocarcinoma Without Progression After Six Cycles of XELOX (Capecitabine Plus Oxaliplatin) Followed by Capecitabine Maintenance or Clinical Observation
Lee GJ, et al. J Gastric Cancer. 2023 Mar;23:e16. https://doi.org/10.5230/jgc.2023.23.e16
- Open Access
- 1 January 2023
- Published by XMLink in Yonsei Medical Journal
- Vol. 64 (2) , 139-147
Selective Inhibition of PI3K Isoforms in Brain Tumors Suppresses Tumor Growth by Increasing Radiosensitivity
Seol MY, et al. Yonsei Med J. 2023 Jan;64:e15. https://doi.org/10.3349/ymj.2022.0414
- 1 January 2023
- Published by XMLink in Yonsei Medical Journal
- Vol. 64 (2) , 139-147
Open AccessSelective Inhibition of PI3K Isoforms in Brain Tumors Suppresses Tumor Growth by Increasing Radiosensitivity
Seol MY, et al. Yonsei Med J. 2023 Jan;64:e15. https://doi.org/10.3349/ymj.2022.0414
- Open Access
- 27 December 2020
- Published by Wiley in Cancer Medicine
- Vol. 10 (3) , 1057-1065
Elevated serum substance P level as a predictive marker for moderately emetogenic chemotherapy‐induced nausea and vomiting: A prospective cohort study
Chemotherapy‐induced nausea and vomiting (CINV) is an unbearable side effect. Identifying high emetic risk patients and providing more active antiemetics strategies are mandatory to improve the tolerability of chemotherapy. In this prospective cohort study, leptin, ghrelin, and substance P were measured at baseline, day 3, and day 14 during the first cycle of chemotherapy. Nausea and vomiting were measured each day for the first 4 days of the first cycle of chemotherapy. Eighty‐two patients were enrolled. Colorectal cancer (61%) and gastric cancer (35.4%) were common cancer types. All patients received moderate emetic risk chemotherapy. Forty‐five (54.9%) patients had nausea, and 15 (18.3%) patients experienced vomiting. In univariate analysis, a higher level of baseline substance P, which is a target of NK1‐RA (Neurokinin 1 receptor antagonist), was a significant predictive marker for chemotherapy‐induced nausea [odds ratio (OR): 2.6, 95% confidence interval (CI): 1.02–6.62, p = 0.046]. Regarding chemotherapy‐induced vomiting, patients with higher levels of substance P had a greater chance of vomiting [OR: 1.72, 95% CI: 0.49–5.99, p = 0.395] than those with lower levels of substance P. In patients receiving moderate emetic risk chemotherapy, active antiemetics, including NK1‐RA, could be considered for those with high levels of substance P.
- 27 December 2020
- Published by Wiley in Cancer Medicine
- Vol. 10 (3) , 1057-1065
Open AccessElevated serum substance P level as a predictive marker for moderately emetogenic chemotherapy‐induced nausea and vomiting: A prospective cohort study
Chemotherapy‐induced nausea and vomiting (CINV) is an unbearable side effect. Identifying high emetic risk patients and providing more active antiemetics strategies are mandatory to improve the tolerability of chemotherapy. In this prospective cohort study, leptin, ghrelin, and substance P were measured at baseline, day 3, and day 14 during the first cycle of chemotherapy. Nausea and vomiting were measured each day for the first 4 days of the first cycle of chemotherapy. Eighty‐two patients were enrolled. Colorectal cancer (61%) and gastric cancer (35.4%) were common cancer types. All patients received moderate emetic risk chemotherapy. Forty‐five (54.9%) patients had nausea, and 15 (18.3%) patients experienced vomiting. In univariate analysis, a higher level of baseline substance P, which is a target of NK1‐RA (Neurokinin 1 receptor antagonist), was a significant predictive marker for chemotherapy‐induced nausea [odds ratio (OR): 2.6, 95% confidence interval (CI): 1.02–6.62, p = 0.046]. Regarding chemotherapy‐induced vomiting, patients with higher levels of substance P had a greater chance of vomiting [OR: 1.72, 95% CI: 0.49–5.99, p = 0.395] than those with lower levels of substance P. In patients receiving moderate emetic risk chemotherapy, active antiemetics, including NK1‐RA, could be considered for those with high levels of substance P.
- Open Access
- 1 January 2019
- Published by Yonsei University College of Medicine in Yonsei Medical Journal
- Vol. 60 (7) , 604-610
Significance of Metabolic Tumor Volume and Total Lesion Glycolysis Measured Using 18F-FDG PET/CT in Locally Advanced and Metastatic Gallbladder Carcinoma
Chun YJ, et al. Yonsei Med J. 2019 Jul;60(7):604-610. https://doi.org/10.3349/ymj.2019.60.7.604
- 1 January 2019
- Published by Yonsei University College of Medicine in Yonsei Medical Journal
- Vol. 60 (7) , 604-610
Open AccessSignificance of Metabolic Tumor Volume and Total Lesion Glycolysis Measured Using 18F-FDG PET/CT in Locally Advanced and Metastatic Gallbladder Carcinoma
Chun YJ, et al. Yonsei Med J. 2019 Jul;60(7):604-610. https://doi.org/10.3349/ymj.2019.60.7.604